FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Schroeder Theodore R 		2. Issuer Name and Ticker or Trading Symbol

CADENCE PHARMACEUTICALS INC [ CADX ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
President, CEO
(Last)          (First)          (Middle)

C/O CADENCE PHARMACEUTICALS, INC., 12481 HIGH BLUFF DRIVE, SUITE 200 		3. Date of Earliest Transaction (MM/DD/YYYY)

3/19/2014
(Street)

SAN DIEGO, CA 92130
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
common stock   3/19/2014     U    12664   D $14.00   0   D    
common stock   3/19/2014     U    307500   D $14.00   0   I   by the Schroeder Living Trust   (1)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
stock option (right to buy)   $1.36   3/19/2014     D         510935      (2) 5/8/2016   common stock   510935   $12.64   0   D    
stock option (right to buy)   $15.13   3/19/2014     D         100000      (3) 3/21/2017   common stock   100000   $0.00   0   D    
stock option (right to buy)   $6.01   3/19/2014     D         400000      (2) 3/17/2018   common stock   400000   $7.99   0   D    
stock option (right to buy)   $8.35   3/19/2014     D         200000      (2) 3/17/2019   common stock   200000   $5.65   0   D    
stock option (right to buy)   $9.22   3/19/2014     D         35000      (2) 3/25/2020   common stock   35000   $4.78   0   D    
stock option (right to buy)   $9.22   3/19/2014     D         150000      (2) 3/25/2020   common stock   150000   $4.78   0   D    
stock option (right to buy)   $8.55   3/19/2014     D         500000      (2) 3/16/2021   common stock   500000   $5.45   0   D    
stock option (right to buy)   $3.51   3/19/2014     D         350000      (2) 3/14/2022   common stock   350000   $10.49   0   D    
stock option (right to buy)   $3.51   3/19/2014     D         164074      (2) 3/14/2022   common stock   164074   $10.49   0   D    
stock option (right to buy)   $5.40   3/19/2014     D         400000      (2) 3/13/2023   common stock   400000   $8.60   0   D    
restricted stock units   $0.00   3/19/2014     D         400000      (4)   (4) common stock   400000   $14.00   0   D    

Explanation of Responses:
( 1)  Mr. Schroeder is the trustee of this trust.
( 2)  In connection with the merger of Cadence Pharmaceuticals, Inc. ("Cadence") with Madison Merger Sub, Inc. ("Merger Sub") on March 19, 2014, and pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") by and among Cadence, Mallinckrodt plc ("Parent") and Merger Sub, dated February 10, 2014, this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (a) the number of shares of common stock of Cadence underlying such option multiplied by (b) the excess, if any, of $14.00 (the "Offer Price") over the exercise price per share of such option.
( 3)  Pursuant to the terms of the Merger Agreement, this option was cancelled because the exercise price per share of the option exceeded the Offer Price.
( 4)  Pursuant to the terms of the Merger Agreement, these restricted stock units were converted into a right to receive a cash payment upon vesting equal to the product of the Offer Price, without interest, and the number of shares of Cadence common stock subject to this grant (the "Converted Award"). The Converted Award will vest in accordance with the original vesting schedule of the restricted stock units, subject to accelerated vesting upon the earlier to occur of (a) September 11, 2014 or (b) certain terminations of the reporting person's employment as set forth in the Merger Agreement.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Schroeder Theodore R
C/O CADENCE PHARMACEUTICALS, INC.
12481 HIGH BLUFF DRIVE, SUITE 200
SAN DIEGO, CA 92130 		X
President, CEO

Signatures
/s/ Hazel M. Aker, Attorney-in-fact 3/21/2014
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
(MM) (NASDAQ:CADX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024 Click Here for more (MM) Charts.
(MM) (NASDAQ:CADX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024 Click Here for more (MM) Charts.